Epitalon and sleep are linked through its studied effect on the pineal gland and melatonin.
- The FDA found no published study of Epitalon in people with insomnia.
- Its one human melatonin trial measured a urine marker in women aged 40 to 50, never sleep.
- Epitalon is off the 503A list; an HHS policy has covered compounded injections of it since 28 October 2026.

GLP-1 medications disrupt sleep for a meaningful subset of users. The GLP-1 sleep guide explains why that happens. You already know sleep is a problem, and you’re reading about Epitalon and sleep to find out whether the peptide is worth understanding.
The short version is that the mechanism is coherent and the research is real, but the evidence has real limits that most of what is written about it online leaves out.
Regulatory status varies by country, and the rules described here are the US ones. Australian residents should consult TGA guidance. UK residents should consult MHRA guidance.
On 24 July 2026, the FDA’s advisory committee recommended Epitalon for the 503A compounding list against the advice of the FDA’s own reviewers, whose briefing document found the criteria weigh against listing it. Six of the seven peptides heard over the two days were backed. Mintz reports that only emideltide was voted down.
This is a recommendation, not a rule. The next step still sits with the FDA, either rulemaking to add the peptide to the list or a move into Category 1 of its interim enforcement policy, which Mintz names as the other route, and the FDA’s own 503A page still shows a list amendment it proposed in 2019 waiting for a final rule. HHS moved separately on 28 October 2026: its interim policy says it does not intend to take enforcement action against pharmacies that compound Epitalon as an injection given in intermittent courses, under ten conditions. Full detail is in the July 2026 peptide FDA decision.
Table of Contents
Disclosure: This article contains affiliate links. If you purchase through these links I may earn a small commission at no extra cost to you.
What Is Epitalon?
Epitalon (also written as Epithalon) is a synthetic tetrapeptide, meaning it is a chain of four amino acids: alanine, glutamic acid, aspartic acid, and glycine. The sequence is abbreviated AEDG. Researchers led by Vladimir Khavinson in St Petersburg first made it in the late 1980s, according to the FDA’s review, basing it on Epithalamin, a polypeptide extract from cattle pineal glands.
The original research interest was longevity and aging. Khavinson’s group found that the pineal gland produced bioregulatory peptides that appeared to influence aging processes, and Epitalon was synthesised as a shorter, more stable version of the natural extract for research purposes.
It is available in research markets as an injectable peptide but is not approved by the FDA for any clinical use (the FDA’s review records no approved drug containing it) and is not on the 503A list; since 28 October 2026 an interim HHS policy has covered compounded Epitalon injections. Sourcing it through grey-market or research chemical suppliers falls outside legal compounding frameworks and carries no quality or safety oversight. I don’t recommend or link to any such sources.
What Does the Research Say About Epitalon and Sleep?
The connection between Epitalon and sleep runs through the pineal gland. The pineal gland produces melatonin, the hormone that signals the brain to initiate sleep and regulates circadian rhythm. Melatonin production declines with age, though the FDA’s review notes that low melatonin has not been consistently linked to insomnia in older adults.
A 2025 review in the International Journal of Molecular Sciences covers Epitalon’s studied biological properties across the literature. The researchers describe Epitalon raising AANAT, the enzyme behind melatonin synthesis, and the signalling protein pCREB in cultured rat pineal cells, and stimulating melatonin synthesis in old rhesus monkeys given it by injection.
In a trial of 75 women, mostly night-shift workers, the 40 with low melatonin were split between Epitalon (0.5 mg a day under the tongue for 20 days) and a placebo spray (per the FDA’s briefing document), and the review reports urinary 6-sulfatoxymelatonin, the marker for melatonin production, rising 1.6 times against placebo. The same review carries one experiment that found nothing: in isolated rat pineal glands, Epitalon changed melatonin release at no dose and at neither age. The proposed mechanism is that Epitalon acts on pinealocytes (the melatonin-producing cells of the pineal gland), upregulating the enzymatic processes involved in melatonin synthesis.
As a foundation: melatonin’s role as a sleep-regulatory hormone is well established in the scientific literature, independent of Epitalon. A review of melatonin as a pineal hormone in Archives of Endocrinology and Metabolism outlines how melatonin synthesis is timed to the light-dark cycle via the suprachiasmatic nucleus. That timing makes melatonin an internal synchroniser of the body’s daily rhythms, sleep included. If Epitalon does stimulate pineal melatonin production, the sleep relevance is plausible, but the FDA’s review calls the effect of such melatonin changes unclear without trials that measure sleep.
The problem is the evidence base for Epitalon’s effect on human sleep specifically.
| What the Epitalon sleep evidence has | What it would take to call it evidence | |
|---|---|---|
| Mechanism | A melatonin-making enzyme raised in cultured rat pineal cells; melatonin synthesis stimulated in old monkeys. One isolated-gland study found nothing. | Independent repeats of the cell work. |
| Who did the work | Most of the human work comes from one group in St Petersburg. | Replication by teams with no stake in the original finding. |
| Trial design | Few controlled trials. The FDA found one on melatonin, and it did not measure sleep. | Trials that assign people at random and compare against a dummy treatment. |
| How many people | 75 women in that trial, 40 of them split between Epitalon and placebo. | Hundreds. |
| Which people | The one melatonin trial the FDA found enrolled women aged 40 to 50, mostly night-shift workers. | People whose sleep is disrupted for other reasons. |
| People like you | No study has looked at GLP-1 users. | One. |
Does Epitalon Improve Sleep?
Nobody has shown that it does. Most of what is known about Epitalon and sleep comes from Khavinson et al.’s own research program at the St Petersburg Institute of Bioregulation, a literature base that is real but methodologically limited by modern trial standards.
The most recent outside look at that literature is the FDA’s own, in its July 2026 briefing document on Epitalon, and it is blunt. Its search “did not retrieve publications discussing efficacy” (whether it works) of Epitalon in people with insomnia.
The one human study it found on melatonin (Ivko et al., 2021) was randomised and placebo-controlled (people were assigned by chance, and some got a dummy treatment), though the FDA notes the paper does not say whether it was blinded. It enrolled 75 women aged 40 to 50, mostly night-shift workers, gave Epitalon or a placebo spray only to the 40 with low melatonin, and tracked a melatonin marker in urine. In the FDA’s words, it “did not evaluate sleep outcomes.” That is a starting point. It is not clinical evidence.
The specific limitations:
The trial was small: 75 women, and only the 40 with low melatonin were given Epitalon or a placebo. It is also the only trial on melatonin the FDA found, and it measured melatonin rather than sleep, according to the FDA’s review. Those women were mostly night-shift workers, so the findings may not translate to people whose sleep disruption has a different cause, including GLP-1-related changes.
That’s not a reason to dismiss the research entirely. Epitalon’s effect on melatonin production has been reported in cultured pineal cells and in old monkeys. The mechanism is coherent. But coherent mechanism plus limited human data is not the same as clinical evidence that it works.
Why Are GLP-1 Users Researching Epitalon?
GLP-1 medications change sleep for a subset of users in ways that are still being characterised. The causes are not settled.
If melatonin regulation is involved in any of those disruptions, a peptide that supports pineal function has a plausible connection. That’s the honest case for GLP-1 users researching Epitalon and sleep: the mechanism is a reasonable fit for the problem, and the sleep disruption many people experience on GLP-1 medication is real enough to motivate looking into options that go beyond standard sleep hygiene.
The gap is that nobody has studied Epitalon specifically in GLP-1 users, and the existing evidence base doesn’t provide a clear route to recommending it as an intervention even if it were legally available.
What Does the July 2026 FDA Review Mean?
Epitalon was one of three peptides heard by the FDA’s Pharmacy Compounding Advisory Committee (PCAC) on July 24, 2026, alongside Semax and Emideltide (DSIP). Epitalon and Semax were recommended. Emideltide was not, which makes it the only one of the seven the committee turned down, as Mintz summarised the two days. That last point matters if you are searching for a sleep peptide, because emideltide is DSIP, the delta sleep-inducing peptide, and it is the one compound on the agenda evaluated specifically for insomnia alongside Epitalon. The committee backed Epitalon and rejected DSIP.
Each of these peptides was reviewed for between one and three named uses rather than for the broad wellness claims made in the market, and FDA’s meeting page for July 23 and 24 lists those uses substance by substance. BPC-157, for instance, was assessed only for ulcerative colitis.
For Epitalon the assessed use was insomnia. Here, unusually, the use on the table is the use people are reading about.
The broader context for that review is covered in the July 2026 peptide FDA decision explainer. The short version here: the PCAC review is advisory only. It is not a legalisation decision. The committee recommended Epitalon for the list that permits compounding, and that recommendation is advice to the FDA, which has not opened a rulemaking process on it. If it does, no date can be put on a listing, and it may not come at all.
The July 23 session covered BPC-157, KPV, MOTS-c and TB-500, on the same advisory pathway, and recommended all four, Pharmaceutical Executive reported. Across these peptides, the regulatory position is consistent: coherent research interest, real but limited human data, an advisory recommendation in hand, and compounding that rests on an interim HHS policy rather than the 503A list.
Anything marketing Epitalon in the US without a prescription, or as a research chemical, is operating outside that framework.
As of its 22 April 2026 update, the FDA’s safety-risks list places Epitalon in its table of substances previously in Category 2 whose nominators withdrew them, and the FDA’s briefing document says the agency reviewed it for the committee on its own initiative. That list still says compounded Epitalon “may pose risk for immunogenicity for certain routes of administration” (an immune reaction against the drug itself), and that the FDA has found no safety information for the route proposed. The FDA has posted no minutes, so the official record of the vote is the meeting video. No proposed rule has followed in the Federal Register.
What Can You Do Right Now?
Epitalon is still off the 503A list, and the July 2026 PCAC recommendation is advisory only. Today a pharmacy relies on the HHS interim policy, which HHS can revisit.
If sleep is a problem, Everlywell sells lab tests you order yourself, a cortisol test among them. A cortisol result is useful context for any conversation with a prescriber about sleep and circadian disruption.
Where Does the Epitalon Research Stand?
The Epitalon and sleep research is real, limited, and not yet independently replicated to modern trial standards. The mechanism is coherent. The one human trial on melatonin the FDA found measured the hormone rather than sleep, and no studies have looked at GLP-1 users specifically.
The July 24 PCAC review went Epitalon’s way. That hands the next step to the FDA, which has not started rulemaking and owns what happens next. A full listing, which would put compounding on firmer legal ground than the HHS policy, is not imminent.
For now, the honest position is that Epitalon and sleep is a mechanistically interesting area with a research foundation that hasn’t yet produced the clinical evidence needed to recommend it with confidence. Sleep environment and understanding your own GLP-1 sleep pattern are the practical starting points while the regulatory picture resolves.
When a trial reads out, a compounder pulls one of these compounds, or the FDA changes its position, you’ll hear it from me along with what it means for you. The change and its context arrive in one email.
Unsubscribe anytime.
References
- Araj SK, et al. Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 2025. pmc.ncbi.nlm.nih.gov
- Amaral FG, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Archives of Endocrinology and Metabolism, 2018. pmc.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. FDA Briefing Document: Epitalon-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee, July 2026. fda.gov
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Content current as of 14 May 2026. fda.gov
- Mintz. FDA’s Advisory Committee Votes on Peptides: What It Does and Doesn’t Do. 29 July 2026. mintz.com
- Pharmaceutical Executive. FDA Panel Votes to Loosen Restrictions for Four Peptides. 24 July 2026. pharmexec.com
